The effectiveness of extracorporeal shock wave therapy in lower limb tendinopathy: a systematic review
Semaglutide additionally raises insulin levels to enhance glycemic control, reinforcing satiety and promoting homeostatic eating [8, 9]
Currently, the mainstream therapeutic armamentarium for IBD encompasses conventional agents (5-aminosalicylates, corticosteroids, and traditional immunosuppressants such as azathioprine), biologics, and small-molecule inhibitors, all of which have demonstrated efficacy in inducing and maintaining remission and in ameliorating symptomatic burden
Notice Notice MCD Alert
To view or add a comment, sign in Lillys Oral GLP-1 Orforglipron Outperforms Oral Semaglutide in T2D Eli Lilly and Company reported that its oral GLP-1 RA orforglipron delivered superior glycemic control and weight loss vs Rybelsus in the Phase 3 ACHIEVE-3 head-to-head trial in adults with type 2 diabetes published in The Lancet
baumannii 186 at the MIC breakpoint of 4 g/mL (Fig
